A promising target to treat asthma

July 24, 2013 by Richard C. Lewis

An enzyme known for its role in heart disease may well be a promising target to treat asthma. Researchers from the University of Iowa have found that the enzyme, called CaMKII, is linked to the harmful effects of oxidation in the respiratory tract, triggering asthmatic symptoms. The finding could lead to the development of a drug that would target the CaMKII enzyme, the researchers say.

Asthma affects billions of people worldwide. In the United States, 8.5 percent of the population has , which causes 3,000 deaths and more than $56 billion annually in medical and lost work costs, according to the federal Centers for Disease Control and Prevention. Despite its toll on health and productivity, treatment options remain confined to steroids, which have harmful, even life-threatening, side effects for those with severe cases.

Current treatments don't work well, noted Mark Anderson, professor and chair in internal medicine at the UI and a co-corresponding author on the paper, published July 24 in the journal Science Translational Medicine.

"It's a kind of an epidemic without a clear, ," Anderson says. "The take-home message is that inhibiting CaMKII appears to be an effective anti-oxidant strategy for treating ."

Anderson and co-corresponding author Isabella Grumbach knew from previous work that the CaMKII enzyme played a role in the oxidation of , which can lead to heart disease and heart attacks. The scientists surmised the same enzyme may affect oxidation in the as well.

The team first tested the enzyme in airway muscle cells, but to little effect. They then tried to block the enzyme in the airway lining (epithelial) cells. They noticed that mice with the blocked enzyme had less oxidized CaMKII, no airway muscle constriction and no asthma symptoms. Similarly, mice without the blocked enzyme showed high "," meaning lots of oxidized enzymes in the epithelial cells, a constricted airway and .

"[The study] suggests that these airway lining cells are really important for asthma, and they're important because of the oxidative properties of CaMKII," says Anderson, whose primary appointment is in the Carver College of Medicine. "This is completely new and could meet a hunger for new asthma treatments. Here may be a new pathway to treat asthma."

"Ten years ago, not much was known about what CaMKII does outside of nerve cells and muscle cells in the heart," says Grumbach, associate professor in internal medicine at the UI. "My lab has worked on investigating its function mainly in blood vessels with the long-term goal to use blockers of CaMKII to treat common diseases. We are constantly finding that CaMKII is interesting and important."

The researchers also took tissue samples from the airways of patients with asthma. True to their hypothesis, they found more oxidized enzymes in those patients than in healthy individuals. Taking a step further, the team found that mild asthma patients who inhaled an allergen had a spike in oxidized CaMKII in the epithelial cells just a day later.

"We have this very compelling association," Anderson says, adding that more studies in patients are needed to validate the approach.

The researchers also plan to investigate inhaled drugs that could block the oxidation of theCaMKII , for treating heart disease and asthma. Anderson has a patent and is involved in a company, Allosteros Therapeutics, which is seeking to develop such a drug.

Explore further: Study finds possible link between diabetes and increased risk of heart attack death

Related Stories

Researchers explore PKC role in lung disease

February 25, 2013

New research examines the role of PKC in airway smooth muscle contraction and raises the possibility that this enzyme could be a therapeutic target for treating asthma, COPD, and other lung diseases.

Rewiring DNA circuitry could help treat asthma

July 5, 2012

(Medical Xpress) -- Reprogramming asthma-promoting immune cells in mice diminishes airway damage and inflammation, and could potentially lead to new treatments for people with asthma, researchers have found.

Recommended for you

Zika in fetal brain tissue responds to a popular antibiotic

November 30, 2016

Working in the lab, UC San Francisco researchers have identified fetal brain tissue cells that are targeted by the Zika virus and determined that azithromycin, a common antibiotic regarded as safe for use during pregnancy, ...

Zika and glaucoma linked for first time in new study

November 30, 2016

A team of researchers in Brazil and at the Yale School of Public Health has published the first report demonstrating that the Zika virus can cause glaucoma in infants who were exposed to the virus during gestation.

Flu forecasts successful on neighborhood level

November 30, 2016

Scientists at Columbia University's Mailman School of Public Health developed a computer model to predict the onset, duration, and magnitude of influenza outbreaks for New York City boroughs and neighborhoods. They found ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.